Global Anti-angiogenic Ophthalmic Agents Market is expected to grow at a CAGR of xx% and accounting for a revenue share of $xx MN in 2026 from $xx MN in 2019.

Global Anti-angiogenic Ophthalmic Agents Market: Overview

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
Global Anti-angiogenic Ophthalmic Agents Market: Dynamics

Increasing prevalence of Ocular diseases is the key driving factor for the market growth.

Diabetic retinopathy remains one of the greatest challenges for healthcare system worldwide despite the fact that the incidence of visual acuity impairment in diabetic population has decreased due to examination quality improvement and dynamic observation of patients. According to the World Health Organization, a significant increase worldwide in number of patients with Diabetes Mellitus, is expected to reach 629 million by the year 2045. Along with this, rising prevalence of age-related macular degeneration (AMD), which is the leading cause of severe vision loss among geriatric population in many western countries is also bolstering the market growth. Many treatment options are available to treat the ocular diseases. The Laser Coagulation of the Retina (LCR) is used to treat diabetic retinal lesions. However, despite the proven efficacy of LCR some patients continue to lose their vision despite treatment. This may be due to both the complications of laser treatment (development of serpiginous atrophy and subretinal fibrosis) and resistance to its effects. This factor may restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.
Global Anti-angiogenic Ophthalmic Agents Market: Segment Analysis

By Indication Type, Macular Edema segment is expected to dominate the market.

Macular edema is the build-up of fluid in the macula, an area in the center of the retina. The retina is the light-sensitive tissue at the back of the eye and the macula is the part of the retina responsible for sharp, straight-ahead vision. Fluid buildup causes the macula to swell and thicken, which distorts vision. The current standard of care for macular edema is intravitreal injection or anti-VEGF injection. A recent NEI-supported clinical trial that directly compared the effectiveness of the three drugs for DME found that the drugs performed similarly for patients with mild vision problems. However, Eylea performed better for those with more serious vision loss. The global prevalence of Diabetic Macular Edema (DME) among individuals with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus varies by geographic region, with rates as low as 11.4% in European countries to as high as 45.3% in North American countries.

Global Anti-angiogenic Ophthalmic Agents Market

To Know About The Research Methodology :- Request Free Sample Report
Global Anti-angiogenic Ophthalmic Agents Market: Regional Insights

Global Anti-angiogenic Ophthalmic Agents Market1

North America accounted for largest market share in the year 2019, followed by Europe.

Increasing prevalence of eye related disorders like AMD, cataract, glaucoma, diabetic retinopathy, diabetic macular edema and dry eye disorders in the region and high availability of commercialized Anti-angiogenic Ophthalmic Agents are some of the driving factors for market in the region. Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among people aged 65 years and over in the United States and many western countries. For instance, in 2019, Bausch + Lomb launched Ocuvite Eye Performance vitamin supplements in the U.S. in order to meet the increasing needs of U.S. consumers. Besides this, Europe held the second largest share owing to increasing prevalence of myopic choroidal neovascularization in the region.

Asia Pacific is expected to witness fastest growth.

Increasing prevalence of diabetes and other eye related disorders in Asian countries with rising geriatric population pool who are more susceptible in acquiring these vision impairments will contribute to the market growth.

Global Anti-angiogenic Ophthalmic Agents Market2

The report also helps in understanding Global Anti-angiogenic Ophthalmic Agents Market dynamics, structure by analyzing the market segments and project the Global Anti-angiogenic Ophthalmic Agents Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-angiogenic Ophthalmic Agents Market make the report investor’s guide.

For more information visit@

Scope of the Global Anti-angiogenic Ophthalmic Agents Market Report: Inquire before buying

Global Anti-angiogenic Ophthalmic Agents Market3
By Region:

• North America
• Europe
• South America
Key Players operating in Global Anti-angiogenic Ophthalmic Agents Market:

• Gilead Sciences, Inc.
• Eyetech Inc.
• Becton, Dickinson and Company
• Regeneron Pharmaceuticals, Inc.
• Genentech, Inc.
• Novartis AG
• Allergan plc
• Bayer AG
• Santen Pharmaceutical Co., Ltd.
• Shanghai Pharmaceuticals
• Johnson & Johnson
• Pfizer
• Sun Pharma
• Otsuka Pharmaceutical Co. Ltd
• Daiichi Sankyo
• ERC Labs
• Medicom Health care
• Implandata ophthalmic products GmbH
• The Geuder Group, MORCHER GmbH
• Novamedika
Press Release:

According to the news released in October 2019, Novartis received FDA approval for Beovu, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. Beovu is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy.

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Author's Bio: 

Contact info:

Name: Lumawant Godage



Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908